Bambusa Therapeutics Prices Nasdaq IPO at $16 per Share
Bambusa priced its IPO at $16 per share, offering 10,555,555 shares and expecting approximately $168.9 million in gross proceeds before underwriting discounts and expenses.
Related stories
Fed Vice Chair Says AI Infrastructure Push Adds to Inflation Pressures
Federal Reserve Vice Chair Philip Jefferson said the AI infrastructure buildout is adding to U.S. inflationary pressures, while the technology may deliver productivity gains over t
M impact | CENTRAL_BANK | Nov 14, 2026, 06:53 AM UTC
Pricol Promoters to Sell 38.51% Stake in Autotech Unit to Warburg Pincus
Pricol said its board approved the sale of promoters’ entire 38.51% shareholding in Pricol Autotech Limited to Warburg Pincus.
M impact | MNA | Nov 14, 2026, 02:29 AM UTC
High Arctic Energy Services Agrees to Go-Private Sale to Newport Capital
High Arctic Energy Services entered into a definitive acquisition agreement and announced its intent to make a cash distribution to shareholders.
M impact | MNA | Nov 14, 2026, 01:01 AM UTC
Hall Chadwick Acquisition Sets Shareholder Vote on REEcycle Merger
Hall Chadwick Acquisition announced a shareholder meeting to vote on its merger with REEcycle.
M impact | MNA | Nov 13, 2026, 09:49 PM UTC
Nasdaq Panel Denies NextNRG’s Listing Appeal
Nasdaq’s Hearings Panel denied NextNRG’s request to continue its listing after the company failed to meet the $1.00 minimum bid price and $35 million market value requirements. The
M impact | REGULATION | Nov 13, 2026, 09:15 PM UTC
Nasdaq Composite Falls 229.82 Points (0.91%)
M impact | EQUITY | Nov 13, 2026, 09:10 PM UTC